DK3377059T3 - Hæmmere af cxcr2 - Google Patents
Hæmmere af cxcr2 Download PDFInfo
- Publication number
- DK3377059T3 DK3377059T3 DK16867099.0T DK16867099T DK3377059T3 DK 3377059 T3 DK3377059 T3 DK 3377059T3 DK 16867099 T DK16867099 T DK 16867099T DK 3377059 T3 DK3377059 T3 DK 3377059T3
- Authority
- DK
- Denmark
- Prior art keywords
- cxcr2
- inhibitors
- Prior art date
Links
- 102000002791 Interleukin-8B Receptors Human genes 0.000 title 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257529P | 2015-11-19 | 2015-11-19 | |
| PCT/US2016/062427 WO2017087610A1 (en) | 2015-11-19 | 2016-11-17 | Inhibitors of cxcr2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3377059T3 true DK3377059T3 (da) | 2021-01-11 |
Family
ID=58717757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16867099.0T DK3377059T3 (da) | 2015-11-19 | 2016-11-17 | Hæmmere af cxcr2 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9809581B2 (OSRAM) |
| EP (1) | EP3377059B1 (OSRAM) |
| JP (1) | JP6901479B2 (OSRAM) |
| KR (1) | KR102725791B1 (OSRAM) |
| CN (1) | CN108601766B (OSRAM) |
| AR (1) | AR106757A1 (OSRAM) |
| AU (1) | AU2016355654B2 (OSRAM) |
| BR (1) | BR112018010118B1 (OSRAM) |
| CA (1) | CA3005737C (OSRAM) |
| DK (1) | DK3377059T3 (OSRAM) |
| EA (1) | EA035417B1 (OSRAM) |
| ES (1) | ES2841912T3 (OSRAM) |
| IL (1) | IL259354B (OSRAM) |
| MX (1) | MX382779B (OSRAM) |
| PL (1) | PL3377059T3 (OSRAM) |
| PT (1) | PT3377059T (OSRAM) |
| SG (1) | SG11201804136SA (OSRAM) |
| TW (1) | TWI724056B (OSRAM) |
| WO (1) | WO2017087610A1 (OSRAM) |
| ZA (1) | ZA201803436B (OSRAM) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014100615A1 (en) | 2012-12-20 | 2014-06-26 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| TWI734715B (zh) * | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| US12144850B2 (en) | 2016-04-08 | 2024-11-19 | Purdue Research Foundation | Methods and compositions for car T cell therapy |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| WO2018106931A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| CA3051481A1 (en) | 2017-02-07 | 2018-08-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (ple) car t cell tumor targeting (ctct) agents |
| ES3010559T3 (en) | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| JP2020517259A (ja) | 2017-04-19 | 2020-06-18 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 操作された抗原受容体を発現する免疫細胞 |
| US11130740B2 (en) | 2017-04-25 | 2021-09-28 | Arbutus Biopharma Corporation | Substituted 2,3-dihydro-1H-indene analogs and methods using same |
| RU2020106383A (ru) | 2017-08-14 | 2021-09-16 | Аллерган, Инк. | 3,4-двузамещенные 3-циклобутен-1,2-дионы и их применение |
| IL275839B2 (en) * | 2018-01-08 | 2024-02-01 | Chemocentryx Inc | Methods for the treatment of generalized abscess psoriasis using a CCR6 or CXCR2 antagonist |
| JP7549303B2 (ja) | 2018-01-22 | 2024-09-11 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞の使用方法 |
| CN111936518A (zh) | 2018-02-06 | 2020-11-13 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| CN112105382A (zh) | 2018-02-23 | 2020-12-18 | 恩多塞特公司 | 用于car t细胞疗法的顺序方法 |
| US12083118B2 (en) | 2018-03-29 | 2024-09-10 | Arbutus Biopharma Corporation | Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same |
| US11446289B2 (en) * | 2018-08-29 | 2022-09-20 | Chemocentryx, Inc. | Combination therapy using C-C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors |
| UA128700C2 (uk) | 2018-09-21 | 2024-10-02 | Пфайзер Інк. | N-заміщені діоксоциклобутеніламіно-3-гідроксипіколінаміди, прийнятні як інгібітори ccr6 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN116726361A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| ES2962639T3 (es) * | 2019-04-08 | 2024-03-20 | Pi Industries Ltd | Nuevos compuestos de oxadiazol para controlar o prevenir hongos fitopatógenos |
| IL288144B2 (en) * | 2019-05-15 | 2024-03-01 | Alonbio Ltd | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death |
| MX2022000318A (es) | 2019-07-10 | 2022-02-10 | Chemocentryx Inc | Indanos como inhibidores de pd-l1. |
| CN112274511B (zh) * | 2019-07-22 | 2024-04-02 | 正大天晴药业集团股份有限公司 | 用于治疗移植物抗宿主病的喹啉衍生物 |
| CN114585359B (zh) | 2019-10-16 | 2025-08-12 | 凯莫森特里克斯股份有限公司 | 用于治疗pd-l1疾病的杂芳基联苯酰胺 |
| MX2022004450A (es) | 2019-10-16 | 2022-05-03 | Chemocentryx Inc | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. |
| US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| CN113018438B (zh) * | 2019-12-24 | 2022-06-17 | 四川大学 | Cxcr2抑制剂在制备治疗鼻咽癌的药物中的用途 |
| CN114929225B (zh) * | 2020-01-19 | 2024-06-28 | 正大天晴药业集团股份有限公司 | 用于治疗类风湿性关节炎的喹啉衍生物 |
| WO2021222818A2 (en) * | 2020-04-30 | 2021-11-04 | Gordon Erlinda M | Damage-targeted treatments of disease |
| CN113952453B (zh) * | 2021-10-11 | 2023-01-24 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | Cxcr2抑制剂在制备治疗肿瘤的药物中的应用 |
| CN113995839B (zh) * | 2021-10-11 | 2023-03-03 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | Cxcr2抑制剂在改善肿瘤免疫微环境中的应用 |
| WO2024144816A1 (en) * | 2022-12-30 | 2024-07-04 | Cantex Pharmaceuticals, Inc. | Treatment of immunologically cold solid tumors |
| WO2025149577A1 (en) * | 2024-01-11 | 2025-07-17 | Julius-Maximilians-Universitaet Wuerzburg | 18f-cxcr2 pet tracer |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1268002A (en) | 1917-09-12 | 1918-05-28 | William M Goodwin | Measuring instrument. |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US6166050A (en) | 1998-12-14 | 2000-12-26 | American Home Products Corporation | 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4 |
| AR033803A1 (es) | 2000-03-01 | 2004-01-07 | Smithkline Beecham Corp | Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas |
| CN1454204A (zh) | 2000-05-30 | 2003-11-05 | 史密丝克莱恩比彻姆公司 | Il－8受体拮抗剂 |
| WO2002067919A1 (en) | 2001-01-16 | 2002-09-06 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| ATE346043T1 (de) | 2001-01-16 | 2006-12-15 | Smithkline Beecham Corp | Il-8-rezeptorantagonisten |
| US20030204085A1 (en) | 2001-02-02 | 2003-10-30 | Taveras Arthur G. | 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists |
| IL156793A0 (en) | 2001-02-02 | 2004-02-08 | Schering Corp | 3,4-di-substituted cyclobutene-1,2-diones as cxc chemokine receptor antagonists |
| US7132445B2 (en) | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US20040106794A1 (en) * | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US20040097547A1 (en) | 2001-04-16 | 2004-05-20 | Taveras Arthur G. | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| CA2444031C (en) * | 2001-04-16 | 2012-02-21 | Schering Corporation | 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
| WO2003080053A1 (en) | 2002-03-18 | 2003-10-02 | Schering Corporation | Combination treatments for chemokine-mediated diseases |
| CN100448860C (zh) | 2003-04-18 | 2009-01-07 | 先灵公司 | 合成2－羟基－n,n－二甲基－3－[[2－[[1(r)－(5－甲基－2－呋喃基)丙基]氨基]－3,4－二氧代－1－环丁烯－1－基]氨基]苯甲酰胺 |
| MXPA06008599A (es) | 2004-01-30 | 2006-08-28 | Schering Corp | Polimorfos cristalinos de un ligando receptor de cxc-quimiocina. |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| GB0419481D0 (en) | 2004-09-02 | 2004-10-06 | Cancer Rec Tech Ltd | Isoindolin-1-one derivatives |
| DE102005035742A1 (de) | 2005-07-29 | 2007-02-01 | Merck Patent Gmbh | Quadratsäurederivate II |
| TW200813033A (en) * | 2006-07-07 | 2008-03-16 | Schering Corp | 3, 4-di-substituted cyclobutene-1, 2-diones as CXC-chemokine receptor ligands |
| WO2008055570A1 (de) | 2006-11-07 | 2008-05-15 | Thyssenkrupp Drauz Nothelfer Gmbh | Verfahren und anlage zum herstellen von verstärkten blechplatinen |
| US7691851B2 (en) | 2007-03-07 | 2010-04-06 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
| FR2915147B1 (fr) | 2007-04-17 | 2010-01-15 | Peugeot Citroen Automobiles Sa | Siege pour vehicule automobile convertible en siege enfant dos a la route et vehicule automobile associe. |
| BRPI0812222A2 (pt) | 2007-06-06 | 2014-12-16 | Novartis Ag | Compostos ciclobutenodiona substituídos anti-inflamatórios. |
| CA2692269A1 (en) | 2007-07-03 | 2009-01-08 | Schering Corporation | Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds |
| JP2010532357A (ja) | 2007-07-05 | 2010-10-07 | シェーリング コーポレイション | １，２−置換３，４−ジオキソ−１−シクロブテン化合物における制御された結晶サイズのための方法 |
| WO2009012375A2 (en) | 2007-07-19 | 2009-01-22 | Wyeth | Squarate kinase inhibitors |
| WO2009042907A1 (en) | 2007-09-27 | 2009-04-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| US20110009482A1 (en) | 2007-12-04 | 2011-01-13 | Schering Corporation | Methods of treating copd |
| CN102123988B (zh) | 2008-06-24 | 2013-08-14 | 顶标公司 | 作为烟酰胺抑制剂的方酸衍生物 |
| UA103198C2 (en) | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
| WO2010045303A2 (en) | 2008-10-16 | 2010-04-22 | Schering Corporation | Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof |
| WO2010063802A1 (en) | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
| WO2010091543A1 (en) * | 2009-02-10 | 2010-08-19 | Merck Sharp & Dohme Corp. | Novel hydrazino-cyclobut-3-ene-1, 2-dione derivatives as cxcr2 antagonists |
| WO2010131146A1 (en) | 2009-05-12 | 2010-11-18 | Pfizer Limited | Cyclobutenedione derivatives |
| FR2961695B1 (fr) | 2010-06-29 | 2012-07-06 | Galderma Res & Dev | Utilisation de composes dans le traitement ou la prevention de troubles cutanes |
| US8648070B2 (en) | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments |
| US8648118B2 (en) | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted amide functionalised phenols as medicaments |
| EP2760821B1 (en) | 2011-09-02 | 2017-10-11 | Novartis AG | Choline salt of an anti-inflammatory substituted cyclobutenedione compound |
| FR2981935B1 (fr) | 2011-10-28 | 2015-08-07 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| FR2981934B1 (fr) | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| FR2981936B1 (fr) | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| US9458174B2 (en) | 2012-05-23 | 2016-10-04 | Stemergie Biotechnology Sa | Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof |
| WO2015170430A1 (ja) | 2014-05-08 | 2015-11-12 | 学校法人慶應義塾 | 大動脈解離後の炎症性障害抑制剤 |
| US20170320954A1 (en) | 2014-11-17 | 2017-11-09 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| IL275839B2 (en) | 2018-01-08 | 2024-02-01 | Chemocentryx Inc | Methods for the treatment of generalized abscess psoriasis using a CCR6 or CXCR2 antagonist |
-
2016
- 2016-11-14 TW TW105136997A patent/TWI724056B/zh active
- 2016-11-17 BR BR112018010118-4A patent/BR112018010118B1/pt active IP Right Grant
- 2016-11-17 EA EA201891211A patent/EA035417B1/ru not_active IP Right Cessation
- 2016-11-17 CA CA3005737A patent/CA3005737C/en active Active
- 2016-11-17 SG SG11201804136SA patent/SG11201804136SA/en unknown
- 2016-11-17 JP JP2018526187A patent/JP6901479B2/ja active Active
- 2016-11-17 US US15/353,949 patent/US9809581B2/en active Active
- 2016-11-17 WO PCT/US2016/062427 patent/WO2017087610A1/en not_active Ceased
- 2016-11-17 ES ES16867099T patent/ES2841912T3/es active Active
- 2016-11-17 PT PT168670990T patent/PT3377059T/pt unknown
- 2016-11-17 CN CN201680068015.9A patent/CN108601766B/zh active Active
- 2016-11-17 AU AU2016355654A patent/AU2016355654B2/en active Active
- 2016-11-17 EP EP16867099.0A patent/EP3377059B1/en active Active
- 2016-11-17 PL PL16867099T patent/PL3377059T3/pl unknown
- 2016-11-17 MX MX2018006148A patent/MX382779B/es unknown
- 2016-11-17 DK DK16867099.0T patent/DK3377059T3/da active
- 2016-11-17 KR KR1020187017289A patent/KR102725791B1/ko active Active
- 2016-11-18 AR ARP160103547A patent/AR106757A1/es active IP Right Grant
-
2017
- 2017-10-02 US US15/722,785 patent/US10370363B2/en active Active
-
2018
- 2018-05-14 IL IL259354A patent/IL259354B/en active IP Right Grant
- 2018-05-24 ZA ZA2018/03436A patent/ZA201803436B/en unknown
-
2019
- 2019-06-12 US US16/438,880 patent/US11040960B2/en active Active
-
2021
- 2021-04-29 US US17/243,872 patent/US11945805B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3377059T3 (da) | Hæmmere af cxcr2 | |
| IL263586B (en) | Inhibitors of the menin-mll interaction | |
| DK3371171T3 (da) | Inhibitorer af RET | |
| DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
| DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3164380T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
| DK3160956T3 (da) | Inhibitorer af lysin-specifik demethylase-1 | |
| DK3423451T3 (da) | Inhibitorer af wdr5-protein-proteinbinding | |
| DK3261721T3 (da) | Anvendelse af pridopidin til forbedring af hukommelse | |
| DK3180331T3 (da) | Polymorfer af selinexor | |
| DK3317400T3 (da) | Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter | |
| DK3551625T3 (da) | Heterocykliske inhibitorer af mct4 | |
| DK3512857T3 (da) | Spiro-bicykliske inhibitorer af menin-mll-interaktion | |
| DK3371165T3 (da) | Btk-inhibitor til anvendelse til behandling af kræft | |
| DK3329007T3 (da) | Ortogonal afblokering af nukleotider | |
| DK3283210T3 (da) | Fremgangsmåde | |
| DK3204352T3 (da) | Hæmmere af lysin-gingipain | |
| DK3307267T3 (da) | Behandling af multipel sklerose | |
| DK3227325T3 (da) | Sammensætninger med selektive hæmmere af il-6-trans-signalering | |
| DK3390422T3 (da) | Krystalformer af lnt | |
| DK3418273T3 (da) | Derivater af flavagliner | |
| DK3113773T3 (da) | Krystallinske former af grapiprant | |
| DK3297619T3 (da) | Terapeutiske anvendelser af L-4-chlorkynurenin | |
| DK3368044T3 (da) | Behandling af hepatisk steatose-relateret oligo-ovulation |